Products
Dazodalibep Biosimilar Fusion Protein (CD40L) for Research
Pre-Made Dazodalibep Biosimilar, Fusion Protein targeting CD40LG fused with ALB (albumin, human serum albumin, HSA): Recombinant therapeutic protein targeting CD154/CD40L/HIGM1/IGM/IMD3/T-BAM/TNFSF5/TRAP/gp39/hCD40L is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Dazodalibep is a novel, non-antibody fusion protein that blocks CD40 ligand (CD40L) activity that has been shown to reduce B cell activation and autoantibody production, potentially halting inflammation and autoimmunity.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-798-1mg | 1mg | 3090 |
| GMP-Bios-INN-798-10mg | 10mg | |
| GMP-Bios-INN-798-100mg | 100mg | |
| GMP-Bios-INN-798-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Dazodalibep Biosimilar, Fusion Protein targeting CD40LG fused with ALB (albumin, human serum albumin, HSA): Recombinant therapeutic protein targeting CD154/CD40L/HIGM1/IGM/IMD3/T-BAM/TNFSF5/TRAP/gp39/hCD40L |
| INN Name | Dazodalibep |
| Target | CD40LG |
| Format | Fusion Protein |
| Derivation | synthetic construct |
| Species Reactivity | human |
| CH1 Isotype | Fusion - Alternative to antigen receptors (domain scaffold: TNC-F3, tenascin domain F3) 2 TNC- F3 domains |
| VD LC | Fusion - Alternative to antigen receptors (domain scaffold: TNC-F3, tenascin domain F3) 2 TNC- F3 domains |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Viela Bio, Inc. (Gaithersburg MD USA) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | Alternative to antigen receptors, domain scaffold TNC F3, tenascin domain F3 |
About target - CD40LG
1. Protein CD40 ligand
2. Gene CD40LG
3. Organism Homo sapiens (Human)
Function
Cytokine that acts as a ligand to CD40/TNFRSF5 (PubMed:1280226, PubMed:31331973).
Costimulates T-cell proliferation and cytokine production (PubMed:8617933).
Its cross-linking on T-cells generates a costimulatory signal which enhances the production of IL4 and IL10 in conjunction with the TCR/CD3 ligation and CD28 costimulation (PubMed:8617933).
Induces the activation of NF-kappa-B (PubMed:15067037, PubMed:31331973).
Induces the activation of kinases MAPK8 and PAK2 in T-cells (PubMed:15067037).
Induces tyrosine phosphorylation of isoform 3 of CD28 (PubMed:15067037).
Mediates B-cell proliferation in the absence of co-stimulus as well as IgE production in the presence of IL4 (By similarity).
Involved in immunoglobulin class switching (By similarity).
CD40 ligand, soluble form:
Acts as a ligand for integrins, specifically ITGA5:ITGB1 and ITGAV:ITGB3; both integrins and the CD40 receptor are required for activation of CD40-CD40LG signaling, which have cell-type dependent effects, such as B-cell activation, NF-kappa-B signaling and anti-apoptotic signaling.
